JP2020523014A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020523014A5 JP2020523014A5 JP2019567708A JP2019567708A JP2020523014A5 JP 2020523014 A5 JP2020523014 A5 JP 2020523014A5 JP 2019567708 A JP2019567708 A JP 2019567708A JP 2019567708 A JP2019567708 A JP 2019567708A JP 2020523014 A5 JP2020523014 A5 JP 2020523014A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cancer
- pharmaceutical composition
- surface fucosylation
- reduced surface
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 76
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 67
- 230000033581 fucosylation Effects 0.000 claims description 37
- 150000008267 fucoses Chemical class 0.000 claims description 28
- 241001465754 Metazoa Species 0.000 claims description 20
- 125000004185 ester group Chemical group 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 238000011467 adoptive cell therapy Methods 0.000 claims description 5
- 230000002093 peripheral effect Effects 0.000 claims description 5
- 102000000588 Interleukin-2 Human genes 0.000 claims description 4
- 108010002350 Interleukin-2 Proteins 0.000 claims description 4
- 150000001323 aldoses Chemical group 0.000 claims description 4
- 238000002659 cell therapy Methods 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 4
- 150000003839 salts Chemical group 0.000 claims description 4
- 239000012453 solvate Chemical group 0.000 claims description 4
- SQTFKIKSQNCWGJ-KCDKBNATSA-N (2s,3r,4r,5s)-2-fluoro-3,4,5-trihydroxyhexanal Chemical compound C[C@H](O)[C@@H](O)[C@@H](O)[C@H](F)C=O SQTFKIKSQNCWGJ-KCDKBNATSA-N 0.000 claims description 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 3
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims description 3
- -1 alkynyl fucose Chemical compound 0.000 claims description 3
- 210000003743 erythrocyte Anatomy 0.000 claims description 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 239000006143 cell culture medium Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 210000000952 spleen Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 201000004458 Myoma Diseases 0.000 claims 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 235000009754 Vitis X bourquina Nutrition 0.000 claims 1
- 235000012333 Vitis X labruscana Nutrition 0.000 claims 1
- 240000006365 Vitis vinifera Species 0.000 claims 1
- 235000014787 Vitis vinifera Nutrition 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 206010042863 synovial sarcoma Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 0 *C1C(*)[C@@](*)C(*)O*1 Chemical compound *C1C(*)[C@@](*)C(*)O*1 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762516536P | 2017-06-07 | 2017-06-07 | |
| US62/516,536 | 2017-06-07 | ||
| PCT/US2018/036067 WO2018226701A1 (en) | 2017-06-07 | 2018-06-05 | T cells with reduced surface fucosylation and methods of making and using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020523014A JP2020523014A (ja) | 2020-08-06 |
| JP2020523014A5 true JP2020523014A5 (enExample) | 2021-07-26 |
| JP7245177B2 JP7245177B2 (ja) | 2023-03-23 |
Family
ID=62751563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019567708A Active JP7245177B2 (ja) | 2017-06-07 | 2018-06-05 | 低減した表面フコシル化を有するｔ細胞、及びそれを作製及び使用する方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11891644B2 (enExample) |
| EP (1) | EP3634427A1 (enExample) |
| JP (1) | JP7245177B2 (enExample) |
| KR (1) | KR102687149B1 (enExample) |
| CN (1) | CN110740734A (enExample) |
| AU (1) | AU2018282225B2 (enExample) |
| BR (1) | BR112019025775A2 (enExample) |
| CA (1) | CA3065524A1 (enExample) |
| EA (1) | EA201992875A1 (enExample) |
| IL (1) | IL271012B2 (enExample) |
| MA (1) | MA50865A (enExample) |
| MX (1) | MX2019014584A (enExample) |
| SG (1) | SG11201911617SA (enExample) |
| TW (1) | TW201903144A (enExample) |
| UA (1) | UA128783C2 (enExample) |
| WO (1) | WO2018226701A1 (enExample) |
| ZA (1) | ZA201907623B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021034774A1 (en) * | 2019-08-16 | 2021-02-25 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Fucosylation and immune modulation in cancer |
| US12036286B2 (en) | 2021-03-18 | 2024-07-16 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| WO2022221766A1 (en) * | 2021-04-16 | 2022-10-20 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Fucosylation and immune modulation in cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| WO2012019165A2 (en) * | 2010-08-05 | 2012-02-09 | Seattle Genetics, Inc. | Methods of inhibition of protein fucosylation in vivo using fucose analogs |
| WO2012177925A1 (en) | 2011-06-21 | 2012-12-27 | The Board Institute, Inc. | Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene |
| PT3102609T (pt) | 2014-02-04 | 2024-10-23 | Us Health | Métodos de produção de células t autólogas úteis para o tratamento de malignidades das células b e de outros cancros e respetivas composições |
| US11400115B2 (en) | 2014-04-23 | 2022-08-02 | Juno Therapeutics, Inc. | Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy |
| MX2017000646A (es) | 2014-07-15 | 2017-04-27 | Juno Therapeutics Inc | Celulas geneticamente modificadas para terapia celular adoptiva. |
| MX2017003062A (es) | 2014-09-09 | 2017-12-14 | Unum Therapeutics | Receptores quimericos y usos de los mismos en terapia inmune. |
| EP3227323B1 (en) | 2014-12-03 | 2020-08-05 | Juno Therapeutics, Inc. | Methods and compositions for adoptive cell therapy |
| IL292504B2 (en) | 2015-10-20 | 2024-01-01 | Kite Pharma Inc | Methods of preparing T cells for T cell therapy |
| SG11201804263PA (en) * | 2015-12-04 | 2018-06-28 | Seattle Genetics Inc | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor |
-
2018
- 2018-06-05 IL IL271012A patent/IL271012B2/en unknown
- 2018-06-05 BR BR112019025775-6A patent/BR112019025775A2/pt unknown
- 2018-06-05 JP JP2019567708A patent/JP7245177B2/ja active Active
- 2018-06-05 MA MA050865A patent/MA50865A/fr unknown
- 2018-06-05 WO PCT/US2018/036067 patent/WO2018226701A1/en not_active Ceased
- 2018-06-05 EP EP18734696.0A patent/EP3634427A1/en active Pending
- 2018-06-05 EA EA201992875A patent/EA201992875A1/ru unknown
- 2018-06-05 UA UAA201912290A patent/UA128783C2/uk unknown
- 2018-06-05 CA CA3065524A patent/CA3065524A1/en active Pending
- 2018-06-05 SG SG11201911617SA patent/SG11201911617SA/en unknown
- 2018-06-05 CN CN201880038031.2A patent/CN110740734A/zh active Pending
- 2018-06-05 KR KR1020197037822A patent/KR102687149B1/ko active Active
- 2018-06-05 US US16/616,928 patent/US11891644B2/en active Active
- 2018-06-05 MX MX2019014584A patent/MX2019014584A/es unknown
- 2018-06-05 AU AU2018282225A patent/AU2018282225B2/en not_active Ceased
- 2018-06-07 TW TW107119671A patent/TW201903144A/zh unknown
-
2019
- 2019-11-18 ZA ZA2019/07623A patent/ZA201907623B/en unknown
-
2023
- 2023-12-19 US US18/545,981 patent/US20240117400A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7266630B2 (ja) | ベンゾオキサゼピンオキサゾリジノン化合物及び使用方法 | |
| US11964941B2 (en) | 5-Bromo-indirubins | |
| ES2989617T3 (es) | Moduladores de receptores de quimioquinas y usos de los mismos | |
| EP4551296A1 (en) | Pyrido[4,3-d]pyrimidine compounds | |
| KR102566924B1 (ko) | 케모카인 수용체 조절제 및 이의 용도 | |
| US12071411B2 (en) | Inhibitors of HIF-2α and methods of use thereof | |
| JP2017538725A (ja) | テトラヒドロ−ピリド［３，４−ｂ］インドールエストロゲン受容体モジュレーター及びその使用 | |
| BR112018006025B1 (pt) | Composição farmacêutica e aplicação da mesma | |
| US12281127B2 (en) | Pyrido[4,3-d]pyrimidine compounds | |
| JP2021527051A (ja) | ピラゾロ−ピリミジン−アミノ−シクロアルキル化合物及びその治療的使用 | |
| JP2020523014A5 (enExample) | ||
| BR112021002632A2 (pt) | compostos e composições de ureia como inibidores de smarca2/brm atpase | |
| BR112020020956A2 (pt) | derivados de pladienolida como spliceossoma que tem como alvo agentes para tratar câncer | |
| US9512138B2 (en) | Compositions and methods for treating cancer | |
| WO2024213979A1 (en) | Pyrido[4,3-d]pyrimidine compounds | |
| CN116761606A (zh) | 增强细胞杀伤的药物组合物及其用途 | |
| JP2024056937A (ja) | Ｒａｓ腫瘍性タンパク質の阻害剤、その作製方法及びその使用方法 | |
| US12240837B2 (en) | Chemokine receptor modulators and uses thereof | |
| US20180105550A1 (en) | Cytidine derivative dimers and applications thereof | |
| US10512630B2 (en) | Compositions and methods for treating cancer | |
| US20240140947A1 (en) | Compound for the treatment of cancer | |
| CN110981803B (zh) | 一种抗肿瘤化合物及其合成方法与应用 | |
| Brezicka et al. | Supra-additive cytotoxic effects of a combination of cytostatic drugs and antibody-induced complement activation on tumor cells in vitro | |
| KR20250100539A (ko) | 피리도[4,3-d]피리미딘 화합물 | |
| US20230330080A1 (en) | Therapeutic treatment using protein kinase c (pkc) inhibitors and cytotoxic agents |